Gateshead Health NHS Foundation Trust has issued a preliminary market engagement notice for a cancer management system, as NHS organisations across England face growing pressure to digitise clinical pathways and reduce delays in cancer care. The notice signals the trust's intention to procure a platform capable of managing patients from referral through to treatment, and forms part of a wider national effort to bring cancer services in line with modern digital standards.

The system the trust is seeking would handle end-to-end management of cancer pathways, incorporating patient tracking, multidisciplinary team coordination, treatment planning and clinical data integration. It is important to note that this is not a live tender. 

The notice is a market engagement exercise, intended to help the trust understand what solutions are currently available before it develops a formal procurement strategy. Interested suppliers are being asked to participate in a demonstration phase, during which the trust will assess system capabilities and how well they align with its operational needs.

Suppliers wishing to take part in the demonstration phase must express their interest by 5pm on 22 May. The broader engagement period runs until 30 June 2026. Should procurement proceed as planned, the resulting contract would begin in April 2027 and run initially to March 2030, with an option to extend to March 2032, giving a total contract length of up to five years.

The trust has set out detailed functional requirements for the system. It must support remote monitoring of patients and be capable of capturing and reporting on personalised care. Interoperability is a stated priority, with the system required to import and export records to and from existing clinical infrastructure, including radiology and patient administration systems. 

The platform must also meet national reporting obligations, including the Weekly Cancer Patient Tracking List and the Cancer Waiting Times dataset, both of which are used to monitor performance against NHS targets.

The procurement comes at a time when cancer care digitalisation has moved up the policy agenda. The government published its National Cancer Plan for England earlier this year, backed by substantial investment in digital diagnostics and informed by responses from nearly 12,000 individuals and organisations. 

The plan sets out ambitions for robotic surgery to account for half a million procedures by 2035 and identifies artificial intelligence as a tool to reduce administrative burden on clinical staff. AI is also being positioned to support oncologists in radiotherapy planning, with recommendations from a Getting It Right First Time study into radiotherapy productivity expected to be implemented once published.

Other NHS trusts are already using digital tools to manage specific cancer pathways. Airedale NHS Foundation Trust has deployed robotic process automation to support its prostate cancer pathway. The system identifies patients due for PSA blood tests, sends automated text reminders, and delivers results within 24 hours where they fall within normal range. Where results are outside expected parameters, the system flags those patients for clinical review. The approach removes the need for routine follow-up appointments and reduces the administrative load on clinical teams.

For patients in Gateshead, a successful procurement could mean more consistent tracking through what are often lengthy and complex treatment journeys. The trust's engagement with the market at this stage suggests it is approaching the process carefully, seeking to understand the available options before committing to a specification. 

Whether that translates into a system that meaningfully improves outcomes will depend on implementation, but the direction of travel across the NHS is clear. Digital infrastructure for cancer care is being treated less as an enhancement and more as an operational necessity.